- Home
- DMA vs QNCX Comparison
DMA vs QNCX Comparison
Compare DMA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- QNCX
- Stock Information
- Founded
- DMA 2011
- QNCX 2012
- Country
- DMA United States
- QNCX United States
- Employees
- DMA N/A
- QNCX N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMA Finance
- QNCX Health Care
- Exchange
- DMA Nasdaq
- QNCX Nasdaq
- Market Cap
- DMA 77.0M
- QNCX 62.0M
- IPO Year
- DMA N/A
- QNCX 2019
- Fundamental
- Price
- DMA $8.55
- QNCX $1.40
- Analyst Decision
- DMA
- QNCX Strong Buy
- Analyst Count
- DMA 0
- QNCX 4
- Target Price
- DMA N/A
- QNCX $9.50
- AVG Volume (30 Days)
- DMA 34.6K
- QNCX 110.3K
- Earning Date
- DMA 01-01-0001
- QNCX 03-31-2025
- Dividend Yield
- DMA 2.04%
- QNCX N/A
- EPS Growth
- DMA N/A
- QNCX N/A
- EPS
- DMA N/A
- QNCX N/A
- Revenue
- DMA N/A
- QNCX N/A
- Revenue This Year
- DMA N/A
- QNCX N/A
- Revenue Next Year
- DMA N/A
- QNCX N/A
- P/E Ratio
- DMA N/A
- QNCX N/A
- Revenue Growth
- DMA N/A
- QNCX N/A
- 52 Week Low
- DMA $4.78
- QNCX $0.51
- 52 Week High
- DMA $8.00
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- DMA 44.75
- QNCX 37.98
- Support Level
- DMA $8.51
- QNCX $1.38
- Resistance Level
- DMA $8.78
- QNCX $1.54
- Average True Range (ATR)
- DMA 0.13
- QNCX 0.11
- MACD
- DMA 0.00
- QNCX -0.00
- Stochastic Oscillator
- DMA 28.13
- QNCX 9.37
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.